It is a pentasaccharide composed of five sugars, and the sequence of the five sugars is derived from the portion of heparin that binds to antithrombin. By binding to antithrombin, fondaparinux inhibits factor Xa. (By contrast, low molecular weight heparin has a mean of 15 sugars.)

Fondaparinux is given subcutaneously daily. Clinically, it is used for the prevention of deep vein thrombosis in patients who have had orthopedic surgery as well as for the treatment of deep vein thrombosis and pulmonary embolism.

One potential advantage of fondaparinux over LMWH or unfractionated heparin is that the risk for heparin-induced thrombocytopenia is substantially lower. Furthermore, there have been case reports of fondaparinux being used to anticoagulate patients with established HIT. However, its long half life precludes its use in patients with renal dysfunction.

Read more at Wikipedia.org

• [List your site here Free!]



	FDA Approval of New Anti-Clotting Drug - Arixtra The U.S. Food and Drug Administration (FDA) recently approved fondaparinux sodium (Arixtra) injection for reducing the risk of deep venous thrombosis ... From American Family Physician, 4/15/02 by Monica Preboth

	FDA approves synthetic blood thinner - Updates - Arixtra Injection - Brief Article A new type of blood thinner that reduces the risk of blood clots following hip and knee surgeries has been approved by the FDA. Arixtra Injection (fondaparinux sodium) is the first synthetic opti From FDA Consumer, 3/1/02

	GlaxoSmithKline Submits J-NDAP for Antithrombogenic Agent Fondapariux Sodium Tokyo, Japan, Nov 25, 2005 - (JCNN) - GlaxoSmithKline (GSK) announced on November 24 that it has submitted a New Drug Application (J-NDA) to the Ministry ... From JCNN News Summaries, 11/25/05

	ARIXTRA® Administered the Morning After Orthopedic Surgery Prevented Venous Thromboembolism With Low Risk of Bleeding New Study Published in The Journal Of Arthroplasty PHILADELPHIA, Feb. 3 /PRNewswire/ -- Results from a new study of ARIXTRA(R) (fondaparinux sodium) ... From PR Newswire, 2/3/06

	Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality in hospitalized patients with acute medical illness. The high prevalence ... From CHEST, 8/1/05 by Alex C. Spyropoulos

	A postal survey of current thromboprophylactic practices of consultant orthopaedic surgeons in the treatment of fracture of the hip Despite increasing scientific investigation, the best method for preventing post-operative deep-vein thrombosis remains unclear. In the wake of the publication ... From Journal of Bone and Joint Surgery, 3/1/05 by Watts, A C

	Effects of Pentasaccharide (Fondaparinux) and Direct Thrombin Inhibitors on Coagulation Testing Context.-Direct thrombin inhibitors (DTIs) and fondaparinux represent a new class of anticoagulants. The effects of DTIs on activated partial thromboplastin ... From Archives of Pathology & Laboratory Medicine, 10/1/04 by Gosselin, Robert C

	New concepts in orthopaedic thromboprophylaxis Thromboprophylaxis is a controversial and changing topic. Some have questioned its very need. Various objections have been raised as to its use including ... From Journal of Bone and Joint Surgery, 8/1/04 by Warwick, D

Home

Contact

Resources

Exchange Links

ebay